Ali Shilatifard, PhD, is the Robert Francis Furchgott Professor and Chair of the Department of Biochemistry and Molecular Genetics, and a Professor of Pediatrics, at Northwestern University Feinberg School of Medicine.
As a Jane Coffin Childs postdoctoral fellow, Shilatifard made a seminal contribution to the field of leukemia biology by identifying the first function of any of the mixed-lineage leukemia (MLL) translocation partners, which is when a section of one chromosome changes place with that of another chromosome, creating a mutation. In the 20 years since that discovery, he has dedicated his career to revealing the causes of childhood leukemia and other cancers, and providing detailed molecular insight into the role of epigenetics in cancer.
Research from his laboratory is leading to the development of promising, epigenetic target-specific drugs for childhood leukemia and other forms of cancer. The epigenetic inhibitors developed in the laboratory are currently being tested to treat childhood leukemia, brain cancer, and other solid tumors. His lab has been continuously funded by multiple grants from the National Cancer Institute, the National Institutes of Health, the Leukemia and Lymphoma Society and the American Cancer Society to conduct this research.
Recognition of his work from the scientific and biomedical research communities includes:
- Recipient of the Sword of the American Cancer Society
- AMGEN Award from the American Society for Biochemistry and Molecular Biology
- Inaugural recipient of the Outstanding Investigator Award from the National Cancer Institute
- Elected fellow of the American Association of the Advancement of Science
He is deeply committed to the training and career development of scientists and physician-scientists. In addition to the many students and postdoctoral fellows he’s mentored through his laboratory, Shilatifard is in his 15th year of instructing a three-week Gene Expression course at the Cold Spring Harbor Laboratory. He has presented over 400 invited lectures at scientific meetings and universities in the United States and at international institutes and has organized over 20 international meetings on chromatin, transcription, epigenetics and cancer.
Shilatifard has served as senior editor for the journal Science, and is currently serving as deputy editor for Science Advances, editor for Molecular and Cellular Biology, and a member of eLife's Board of Reviewing Editors. He also serves on the scientific advisory boards of Genentech, the Max Planck Society, and a Biomedicine Jury Member of the BBVA Foundation Frontiers of Knowledge Awards.
See Shilatifard's faculty profile.
Download Shilatifard’s current CV.